Top Gold Stocks To Watch For 2017


Roswell, GA, based Investment company Vident Investment Advisory, LLC buys SPDR S&P 500, Eaton Vance Tax-Advantaged Global Dividend Income , Calamos Strategic Total Return Fund, Calamos Convertible Opportunities and Income Fund, Liberty All-Star Equity Fund, Cohen & Steers Quality Income Realty Fund Inc, BlackRock Credit Allocation Income Trust, John Hancock Tax Advantaged Dividend Income Fund o, Accuray Inc, Hollysys Automation Technologies, sells Royce Value Trust Inc, GAMCO Global Gold Natural Resources & Income Trust, Aberdeen Asia-pacific Income Fund Inc, Calamos Global Dynamic Income Fund, FMC Technologies Inc during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Vident Investment Advisory, LLC. As of 2017-03-31, Vident Investment Advisory, LLC owns 412 stocks with a total value of $975 million. These are the details of the buys and sells.


New Purchases: ETG, CSQ, CHI, USA, RQI, BTZ, HTD, FTI, QGEN, TEI, Added Positions: SPY, ARAY, HOLI, RAVN, OII, FARO, AVAV, IRBT, ROK, ISRG, Reduced Positions: MKSI, BAX, SYY, S, F, UFPI, CVI, FLOW, MU, DGI, Sold Out: RVT, GGN, FAX, CHW, FTI, EXG, PTY, AWP, MENT, GLO,

For the details of Vident Investment Advisory, LLC’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Vident+Investment+Advisory%2C+LLC

Top Gold Stocks To Watch For 2017: Visteon Corporation(VC)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Visteon (VC) : “You need to let this one come down a little, then pull the trigger.”

    American Tower (AMT) : “This is the best in the business and is worth owning, even if the chart looks terrible.”

Top Gold Stocks To Watch For 2017: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Chris Lange]

    Eli Lilly & Co. (NYSE: LLY) saw its shares in free fall on Wednesday, not from the usual rhetoric of politicians or even the election, for that matter, but a late-stage trial failure. As 24/7 Wall St. has said time and again, clinical trials can make or break biotech and pharma companies. In this case Eli Lilly hit new 52-week lows, not seen since 2014 and this will not be a loss that Eli Lilly will easily forget. Effectively, the company announced results from its Phase 3 solanezumab trial in people with mild dementia due to Alzheimers disease (AD).

  • [By Dimitra DeFotis]

    Shares of Eli Lilly (LLY) are down nearly 13% this morning after a late-stage Alzheimer’s drug trial failed to produce expected results.

    Biogen(BIIB), down nearly 6% today, also is working on an Alzheimer’s treatment; Merck (MRK) shareswere down 1% in recent trading.

    Lilly was testing the drug as a treatment for mild dementia due to Alzheimer’s disease.Credit Suisse analysts were hopeful the drug trial would show “a statistically significant impact on cognition.”MarketWatch reports:


    “Eli Lilly said it would not pursue approval for the drug to treat mild dementia due to Alzheimers disease and that it will ‘evaluate the impact of these results on the development plans for solanezumab and our other Alzheimers pipeline assets’ … More specifics about the solanezumab drug, expected the night of Dec. 9 during a meeting of the Clinical Trials on Alzheimers Disease (CTAD), could have repercussions for whats called the beta amyloid hypothesis in Alzheimers disease treatments, which target protein fragments that some believe are responsible for the disease …”


    On Nov. 15, J.P. Morgan analysts Chris Schott, Aditi Singhania, Dana Flanders and Christopher Neyor noted that trial success had a low probability. But they kept their$95 price target on the stock, noting the drug pipeline offers other opportunities. Their target implies upside of more than 40% from a recent price near $66. They wrote:

    “… On solanezumab … While the FDA recommends both cognitive and function endpoints for Alzheimers drug approvals, we expect the agency to review solanezumab on the totality of evidence, and we would not be surprised to see a cognitive benefit coupled with a trend in secondary functional endpoints be sufficient for approval … regardless of the solanezumab outcome, we see a diverse range of new product opportunities supporting LLY

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.

Top Gold Stocks To Watch For 2017: TD Ameritrade Holding Corporation(AMTD)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    TD Ameritrade (AMTD) is very strong today for one reason — it’s a bull market stock — that directly benefits from a rising stock market, explains growth stock expert Mike Cintolo, editor of Cabot Top Ten Trader.

  • [By The Ticker Tape]

    Short-term options traders have priced in a potential share price move of 2.5% in either direction around the earnings release, according to the Market Maker Move™ indicator on the thinkorswim® platform from TD Ameritrade Holding Corp. (NASDAQ: AMTD).

  • [By Chris Dier-Scalise]

    After a another month of record highs for the Dow Jones Industrial Average, which surpassed the $21,000 mark, and the S&P 500, which topped $2,400, TD Ameritrade Holding Corp. (NASDAQ: AMTD) released its March report for the Investor Movement Index. Tracking retail investor movement in and out of equities, the IMX, like the markets at large, hit a new high of 6.22 and showed retail investors were net buyers of equity over the month.

  • [By Dan Caplinger]

    Yet not all brokers decided to match Fidelity. TD Ameritrade (NASDAQ:AMTD) made a reduction in its commission, but by moving from $9.99 to $6.95, the company didn’t close the competitive gap entirely. In justifying that, CEO Tim Hockey said that TD Ameritrade’s clients “have told us time and again that value is delivered via rich experiences that prioritize flexibility and client choice, coupled with a simple, straightforward price.” The company pointed to its trading platforms, tools, product selection, and customer support as marks of distinction for TD Ameritrade over its peers.

Leave a Reply

Your email address will not be published. Required fields are marked *